<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643147</url>
  </required_header>
  <id_info>
    <org_study_id>2014-001433-83</org_study_id>
    <nct_id>NCT02643147</nct_id>
  </id_info>
  <brief_title>Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)</brief_title>
  <acronym>IMPROVE-HF</acronym>
  <official_title>Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación del Hospital Clínico de Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación del Hospital Clínico de Valencia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worsening renal function (WRF) is a frequent finding in patients with decompensated acute
      heart failure (AHF) and it is associated to increased length of hospitalization and higher
      morbidity and mortality. Traditionally, WRF in AHF setting has been attributed to low cardiac
      output, but recent evidence also suggests venous congestion play a crucial role. Loop
      diuretics are the mainstay treatment of AHF, but their use traditionally has been associated
      to WRF, but also renal function improvement in patients with unequivocal signs of congestion.
      Nevertheless, traditional symptoms or signs of patients with AHF have shown a limited
      accuracy to neither identify nor quantify the degree of venous congestion. Recent authors
      have reported that plasma levels of antigen carbohydrate 125 (CA125) are closely related to
      the degree of venous congestion.

      The investigators hypothesize that CA125 may have a role for identifying the hyperhydrated
      (High CA125) patients that need high loop diuretic doses, and those with normal CA125 values
      needing low loop diuretic doses. In this randomized study (1:1) the investigators seek to
      evaluate whether a CA125 loop diuretic guided management therapy is superior to a standard
      strategy. The primary endpoint is the magnitude of changes of renal function at 24 and 72
      hours after initiation of intravenous diuretic in an acute worsening of heart failure
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 30, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in renal function (GFR)</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Glomerular filtration rate (GFR) estimated by MDRD. Prespecified interim analysis of primary outcome will be made by protocol when first 100 patients are included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in signs and symptoms of heart failure (NYHA)</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Evaluation of dyspnea (changes in the functional class of the New York Heart Association -NYHA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in signs and symptoms of heart failure (VAS)</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Evaluation of signs of systemic congestion, and patient global assessment (by visual analogue scale -VAS-)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of natriuretic peptide (NT-proBNP)</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in plasma levels of high sensitive troponin</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time required to change intravenous diuretics to oral administration.</measure>
    <time_frame>Through study completion (30-day follow-up)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of all-cause mortality plus acute heart failure related rehospitalization</measure>
    <time_frame>30 days</time_frame>
    <description>Number of events in each group during 30-day follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function (creatinin)</measure>
    <time_frame>24 h, 72 h and 30 days</time_frame>
    <description>Serum levels of creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function (urea)</measure>
    <time_frame>24 h, 72 h and 30 days</time_frame>
    <description>Serum levels of urea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in renal function (cystatin C)</measure>
    <time_frame>24 h, 72 h and 30 days</time_frame>
    <description>Serum levels of Cystatin C</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>CA125 guided strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group loop diuretic (Furosemide) dosage will be guided by Carbohydrate Antigen 125 (CA125) plasma levels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional strategy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment strategy Therapy is based on established european guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
    <other_name>Loop diuretic (Furosemide) dosage in CA125 ≤35 U/ml patients</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CA125 guided strategy</intervention_name>
    <description>Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.</description>
    <arm_group_label>CA125 guided strategy</arm_group_label>
    <other_name>Loop diuretic dosage (Furosemide) in CA125 &gt;35 U/ml patients</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional Strategy</intervention_name>
    <description>The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations</description>
    <arm_group_label>Conventional strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients with the diagnosis of acute heart failure (AHF) and the concurrence of the
        following conditions:

          1. Presence of symptoms (dyspnea at rest or minimal exertion) and signs attributable to
             congestion (signs of congestion on chest radiography, or presence of peripheral edema
             or ascites, or jugular venous distension at 45 degrees or presence of crackles on
             auscultation).

          2. Elevated natriuretic peptide (NT-proBNP&gt; 1000 pg/ml or BNP&gt; 100 mg/dl).

          3. Creatinine ≥1,4 mg/dl on admission, provided that the estimated glomerular filtration
             rate less than 60 ml / min / m2.

          4. Intent to be treated with loop diuretics intravenously.

        Exclusion Criteria:

          1. Life expectancy less than 6 months of life due to other comorbid conditions.

          2. Cardiogenic shock.

          3. Diagnosis of acute coronary syndrome in the previous 30 days.

          4. Pregnancy at the time of inclusion.

          5. Restrictive or Obstructive pulmonary disease or severe degree.

          6. Chronic renal insufficiency in stage V (estimated glomerular filtration rate &lt;15 ml /
             min / m2) or patient previously included in known dialysis program.

          7. Participation in another clinical trial randomized at the time of inclusion.

          8. Temperature ≥38 ° C or diagnosis of pneumonia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julio Nuñez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>February 11, 2018</last_update_submitted>
  <last_update_submitted_qc>February 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para la Investigación del Hospital Clínico de Valencia</investigator_affiliation>
    <investigator_full_name>Julio Nuñez</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Renal Failure</keyword>
  <keyword>Biomarker guided-therapy</keyword>
  <keyword>Loop diuretics</keyword>
  <keyword>Carbohydrate antigen 125</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

